Jose Manuel Santiago Santana

Dr. Jose Manuel Santiago Santana

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in Journal of Neurotrauma
Verified
Journal Article
Closed access
JCJennifer M. Colón
Jennifer M. Colón
ATAranza Isabel Torrado
Aranza Isabel Torrado
ÁCÁmbar Cajigas
Ámbar Cajigas
JSJose Manuel Santiago Santana
Jose Manuel Santiago Santana
ISIris K. Salgado
Iris K. Salgado
JMJorge David Miranda
Jorge David Miranda
Spinal cord injury (SCI) is a condition with no available cure. The initial physical impact triggers a cascade of molecular and cellular events that generate a nonpermissive environment for cell survival and axonal regeneration. Spinal cord injured patients often arrive at the clinic hours after the initial insult. This indicates the need to study and develop treatments with a long therapeutic window of action and multiactive properties, which target the complex set of events that arise after the initial trauma. We provide evidence that tamoxifen (TAM), a drug approved by the Food and Drug Administration, exerts neuroprotective effects in an animal model when applied up-to 24 h after SCI. We hypothesized that continuous TAM administration will improve functional locomotor recovery by favoring myelin preservation and reducing secondary damage after SCI. Adult female Sprague-Dawley rats (∼230 g) received a moderate contusion to the thoracic (T9–T10) spinal cord, using the MASCIS impactor device. To determine the therapeutic window available for TAM treatment, rats were implanted with TAM pellets (15 mg) immediately or 24 h after SCI. Locomotor function (Basso, Beattie, Bresnahan open field test, grid walk, and beam crossing tests) was assessed weekly for 35 days post-injury. TAM-treated rats showed significant functional locomotor recovery and improved fine movements when treated immediately or 24 h after SCI. Further, TAM increased white matter preservation and reduced secondary damage caused by astrogliosis, axonal degeneration, and cell death after trauma. These results provide evidence for TAM as a potential therapeutic agent to treat SCI up to 24 h after the trauma.

1 January 2018 in Experimental Neurology
Verified
Journal Article
Closed access
JCJennifer M. Colón
Jennifer M. Colón
PGPablo A. González
Pablo A. González
ÁCÁmbar Cajigas
Ámbar Cajigas
WMWanda I. Maldonado
Wanda I. Maldonado
ATAranza I. Torrado
Aranza I. Torrado
JMJorge David Miranda
Jorge David Miranda

Verified
Journal Article
Open access
PDF file
AZAstrid Zayas-Santiago
Astrid Zayas-Santiago
CMChristian J. Malpica-Nieves
Christian J. Malpica-Nieves
DRDavid S. Ríos
David S. Ríos
ADAmanda Marie Díaz-García
Amanda Marie Díaz-García
CMChristian J. Malpica-Nieves
Christian J. Malpica-Nieves
SSSERGUEI N. SKATCHKOV
SERGUEI N. SKATCHKOV
Polyamine (PA) spermidine (SPD) plays a crucial role in aging. Since SPD accumulates in glial cells, particularly in Müller retinal cells (MCs), the expression of the SPD-synthesizing enzyme spermidine synthase (SpdS) in Müller glia and age-dependent SpdS activity are not known. We used immunocytochemistry, Western blot (WB), and image analysis on rat retinae at postnatal days 3, 21, and 120. The anti-glutamine synthetase (GS) antibody was used to identify glial cells. In the neonatal retina (postnatal day 3 (P3)), SpdS was expressed in almost all progenitor cells in the neuroblast. However, by day 21 (P21), the SpdS label was pronouncedly expressed in multiple neurons, while GS labels were observed only in radial Müller glial cells. During early cell adulthood, at postnatal day 120 (P120), SpdS was observed solely in ganglion cells and a few other neurons. Western blot and semi-quantitative analyses of SpdS labeling showed a dramatic decrease in SpdS at P21 and P120 compared to P3. In conclusion, the redistribution of SpdS with aging indicates that SPD is first synthesized in all progenitor cells and then later in neurons, but not in glia. However, MCs take up and accumulate SPD, regardless of the age-associated decrease in SPD synthesis in neurons.

7 October 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Luis Horacio Pagan RiveraLuis Horacio Pagan Rivera
Luis Horacio Pagan Rivera
FGFilipa Godoy-Vitorino
Filipa Godoy-Vitorino
Natalie M. Meléndez-VázquezNatalie M. Meléndez-Vázquez
Natalie M. Meléndez-Vázquez
SOSamuel Ocasio
Samuel Ocasio
MSMaría E. Santiago-Gascot
María E. Santiago-Gascot
JMJorge David Miranda
Jorge David Miranda
Spinal cord injury (SCI) is a devastating neurological state that could lead to motor, sensory, and autonomic dysfunction. In addition to its direct impact on the central nervous system, SCI exerts systemic effects, including disruption of gut homeostasis and alterations in the gut microbiota, which can contribute to sustained inflammation and hinder functional recovery. While antibiotic administration during the acute phase of SCI is clinically indicated, it may exacerbate microbial dysbiosis. In this study, we investigate the combined effects of SCI and cefazolin treatment on the gut microbiome of female rats. Animals were assigned to three groups: NAÏVE (no intervention), SHAM (cefazolin only), and INJURY (T10 spinal cord contusion plus cefazolin). Cefazolin was administered for seven days after the injury, fecal samples were collected at baseline (day 0), and on days 7, 14, 21, and 28 post-SCI. DNA was extracted and subjected to 16S rRNA gene amplicon sequencing, followed by bioinformatic analysis. Our findings revealed significant microbial dysbiosis in the INJURY group, including reduced alpha diversity and distinct shifts in microbial composition. These changes were most prominent during the acute phase post-SCI. Our findings highlight the compounding effects of spinal trauma and antibiotic exposure on the gut microbiome and suggest that maintaining microbial stability may represent a promising avenue to support recovery after SCI.

1 March 2023
Verified
Journal Article
Closed access
LGLyanne M García-Sánchez
Lyanne M García-Sánchez
JCJennifer M Colón-Mercado
Jennifer M Colón-Mercado
ATAranza I Torrado-Tapias
Aranza I Torrado-Tapias
KPKenneth Padín-Díaz
Kenneth Padín-Díaz
JMJorge D Miranda
Jorge D Miranda
JSJose Manuel Santiago Santana
Jose Manuel Santiago Santana

5 October 2020 in Baylor University Medical Center Proceedings
Verified
Journal Article
Open access
MPMimi Phan
Mimi Phan
KBKrista L. Birkemeier
Krista L. Birkemeier
MCMatthew Crisp
Matthew Crisp
JSJose Manuel Santiago Santana
Jose Manuel Santiago Santana
NMNicholas William McGregor
Nicholas William McGregor
In rare instances, pediatric Langerhans cell histiocytosis (LCH) may manifest as lung disease. While the imaging features at presentation have been reported, we present sequential computed tomography (CT) scans of a 3-year-old boy with pulmonary LCH, revealing the evolution and regression of the disease. Sequential CT scans during treatment demonstrated variable evolution of pulmonary cysts, including changes in size, thinning of walls, and a pattern of collapse into irregular nodules and involution. Our case represents a rare opportunity to examine sequential CT findings of pediatric pulmonary LCH regression.